Skip to main content
. 2023 Jan 30;10(2):e200084. doi: 10.1212/NXI.0000000000200084

Figure 2. Depletion and Phenotypical Changes of CD20+ B-Cell Subsets on OCRE.

Figure 2

PBMCs were analyzed as in Figure 1. (A) CD20 expression across FlowSOM unsupervised clustering allows to discriminate the major CD20-expressing nodes including B cells (nodes 7, 8, and 16), CD4+ T cells (nodes 47, 56, and 61), and CD8+ T cells (nodes 24 and 36). (B) Changes in the frequency of FlowSOM unsupervised naive and memory CD20+ B-cell subsets overtime (T0, T6, and T12). The asterisks (*) represent significant differences for the effect of time for a given treatment on a given metacluster: ***p < 0.001 using a nonparametric paired post hoc Nemenyi test. (C) Statistical heatmap expression analyses of markers of function/activation of CD20+ B-cell subsets overtime (T0, T6, and T12). Effect of the treatment overtime and over CD20+ nodes was tested using a nonparametric paired Friedman test as compared to baseline (T0, squares). If significant, a nonparametric paired post hoc Nemenyi test was run to compare baseline values with subsequent time points (T0 vs T6 and T0 vs T12). Post hoc results are depicted as circles (the smallest being not significant and the largest, p < 0.001, see the figure for details). OCRE = ocrelizumab; PBMCs = peripheral blood mononuclear cells.